Predicting treatment response in castration-resistant prostate cancer: could androgen receptor variant-7 hold the key?
- 30 December 2014
- journal article
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 15 (2) , 143-145
Abstract
There is an emerging interest in understanding mechanisms of response and resistance to next-generation hormonal therapies: abiraterone and enzalutamide. While many explanations for resistance to these agents have been postulated, the importance of androgen receptor splice variants is gaining momentum. Androgen receptor (AR) splice variants are constitutively active isoforms of the AR that lack the ligand-binding domain yet retain their transcriptional activity in a ligand-independent fashion. Of these, AR variant-7 may be the most important, and has been implicated in primary resistance to abiraterone and enzalutamide in men with advanced prostate cancer. In this editorial, the clinical relevance of AR splice variant-7 (AR-V7) will be reviewed within the context of AR-directed therapies, and next steps for the analytical and clinical validation of this potential biomarker will be proposed.Keywords
This publication has 16 references indexed in Scilit:
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate CancerNew England Journal of Medicine, 2014
- Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancerEndocrine-Related Cancer, 2014
- Androgen Receptor Splice Variants in the Era of Enzalutamide and AbirateroneDiscover Oncology, 2014
- thanks to referees 2013Annals of Oncology, 2014
- An androgen receptor N-terminal domain antagonist for treating prostate cancerJournal of Clinical Investigation, 2013
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyNew England Journal of Medicine, 2012
- Molecular States Underlying Androgen Receptor Activation: A Framework for Therapeutics Targeting Androgen Signaling in Prostate CancerJournal of Clinical Oncology, 2012
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate CancerScience, 2009
- Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate CancerCancer Research, 2008